Browsing All Christie Publications by Authors
ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.Abou-Alfa, G; Qin, S; Ryoo, B; Lu, S; Yen, C; Feng, Y; Lim, H; Izzo, F; Colombo, M; Sarker, D; et al. (2018-04-05)Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme - arginine deiminase - conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy.
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1Oh, DY; Chen, LT; He, AR; Okusaka, T; Qin, S; Chin, S; Rokutanda, N; Uchinda, H; Vogel, A; Valle, Juan W; et al. (2019)